A genetic approach to ischemic stroke therapy

Cerebrovascular Diseases

Volumn 17, Issue SUPPL. 1, 2004, Pages 63-69

  Vila, Nicolás ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Gene therapy; Monogenic disorders; Pharmacogenetics; Stem cells; Stroke grafts; Stroke therapy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA GALACTOSIDASE; ALPHA2 INTEGRIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTITHROMBOCYTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BLOOD CLOTTING FACTOR 9; CHOLESTEROL ESTER TRANSFER PROTEIN; COLLAGEN RECEPTOR; COLLAGEN TYPE 1; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; LIPOSOME; NAKED DNA; NEUROPROTECTIVE AGENT; NUCLEIC ACID; PRAVASTATIN; PROTEIN P53; STATIN; TRANSCRIPTION FACTOR; VASCULOTROPIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VERY LATE ACTIVATION ANTIGEN 2; VIRUS VECTOR; WARFARIN;

ANGIOGENESIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD BRAIN BARRIER; BLOOD VESSEL INJURY; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CADASIL; CELL DIFFERENTIATION; CELL GROWTH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY STENT; COUGHING; DNA MICROARRAY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG METABOLISM; DRUG TARGETING; ENZYME REPLACEMENT; FABRY DISEASE; GENE EXPRESSION; GENE REPLICATION; GENE TARGETING; GENE THERAPY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MELAS SYNDROME; NEUROPROTECTION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEIC ACID TRANSPORT; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RESTENOSIS; SMOOTH MUSCLE RELAXATION; STEM CELL TRANSPLANTATION; TARGET ORGAN; THROMBOCYTE AGGREGATION; THROMBOSIS; TRANSGENE; VASCULAR DISEASE; VIRAL GENE DELIVERY SYSTEM;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; STEM CELL TRANSPLANTATION;

EID: 0346157362     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074797     Document Type: Conference Paper

References (51)

1. Hachinski V: Stroke: The next 30 years. Stroke 2002;33:1-4.
2. Albers MJ: Impact of the human genome projects and identification of a stroke gene. Stroke 2001;32:1239-1241.
3. Isner JM: Myocardial gene therapy. Science 2002;415:234-238.
4. Heistad DD, Faraci F: Gene therapy for cerebral vascular disease. Stroke 1996;27:1688-1693.
5. Sapolsky RM, Steinberg GK: Gene therapy using viral vectors for acute neurologic insults. Neurology 1999;53:1922-1931.
6. Ferber D: Gene therapy: Safer and virus free? Science 2001;294:1638-1642.
7. Yenari MA, Dumas TC, Sapolsky RM, Steinberg GK: Gene therapy for treatment of cerebral ischemia using defective herpes simplex viral vectors. Ann NY Acad Sci 2001;939:340-357.
8. Ooboshi H, Ibayashi S, Takada J, Yao H, Kitazono T, Fujishima M: Adenovirus-mediated gene transfer to ischemic brain. Stroke 2001;32:1043-1047.
9. Taniyama Y, Tachibana K, Hiraoka K, Namba T, Yamasaki K, Hashiya N, et al: Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation 2002;105:1233.
10. Akins PT, Liu PK, Hsu CY: Immediate early gene expression in response to cerebral ischemia: Friend or foe? Stroke 1996;27:1682-1687.
11. Betz AL, Yang GY, Davidson BL: Attenuation of stroke size in rats using an adenoviral vector to induce overexpression of interleukin-1 receptor antagonist in brain. J Cereb Blood Flow Metab 1995;15:547-551.
12. Linnik MD, Zahos P, Geschwind MD, Federoff HJ: Expression of bcl-2 from a defective herpes simplex virus-1 vector limits neuronal death in focal cerebral ischemia. Stroke 1995;26:1670-1674.
13. Lawrence MS, Sun GH, Kunis DM, Saydam TC, Dash R, Ho DY, et al: Overexpression of the glucose transporter gene with a herpes simplex viral vector protect striatal neurons against stroke. J Cereb Blood Flow Metab 1996;16:181-185.
14. Yenari M, Fink S, Sun G: Gene therapy with hsp72 is neuroprotective in rat models of stroke and epilepsy. Ann Neurol 1998;44:584-591.
15. Khurana R, Martin JF, Zachary I: Gene therapy for cardiovascular disease. Hypertension 2001;38:1210-1216.
16. Ooboshi H, Toyoda K, Faraci FM, Lang MG, Heistaad DD: Improvement of relaxation in an atherosclerotic artery by gene transfer of endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 1998;18:1752-1758.
17. Teupe C, Richter S, Fisslthaler B, Randriamvoabonjy V, Ihling C, Fleming I, et al: Vascular gene transfer of phosphomimetic endothelial nitric oxide synthase using ulltrasound-enhanced destruction of plasmid-loaded micro-bubbles improves vasoreactivity. Circulation 2002;105:1104-1108.
18. Morishita R, Gibbons GH, Ellison KE: Intimal hyperplasia after vascular injury is inhibited by antisense cdk2 kinase oligonucleotides. J Clin Invest 1994;93:1458.
19. Klugherz BD, Cunxian S, Hinson JT, DeFelice S, Cui X, Lu Z, et al: Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. Hum Gene Ther 2002;13:443-454.
20. Leclerc G, Gal D, Takeshita S: Percutaneous arterial gene transfer in rabbit model: Efficiency in normal and balloon-dilated atherosclerotic arteries. J Clin Invest 1992;90:936.
21. Brady RO, Schiffmann R: Clinical features of and recent advances in therapy for Fabry disease. JAMA 2000;284:2771-2775.
22. Eng CM, Guffon N, Wilcox WR, Germain PG, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ: Safety and efficacy of recombinant human alfa-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16.
23. Amouyel P: A critical assessment of the role of pharmacogenomics and pharmacogenetic approaches to cardiovascular diseases. Pharmacogenomic J 2001;1:95-100.
24. King HC, Sinha AA: Gene expression profile analysis by DNA microarrays. JAMA 2001;286:2280-2288.
25. Evans WE, Relling MV: Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999;286:487-491.
26. Meyer UA: Pharmacogenetics and adverse drug reactions. Lancet 2000;356:1667-1671.
27. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA 2001;286:2270-2279.
28. Aithal GP, Day CP, Kesteven PJL, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1998;353:717-719.
29. Oldenburg J, Kriz K, Wuillemin WA, Maly FE, von Felten A, Siegemund A, et al: Genetic predisposition to bleeding during oral anticoagulant therapy: Evidence for common founder mutations and an independent CpG hotspot mutation. Thromb Hemost 2001;85:454-457.
30. Gorter JW: Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors. Stroke Prevention in Reversible Ischemia Trial (SPRIT), European Atrial Fibrillation Trial (EAFT) study groups. Neurology 1999;53:1319-1327.
31. Takami S, Imai Y, Katsuya T, Ohkubo T, Tsuji I, Nagai K, et al: Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. Am J Hypertens 2000;13:121-127.
32. Elbaz A, Poirier O, Moulin T, Chedru F, Cambien F, Amarenco P: Association between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain infarction. Stroke 2000;31:1634-1639.
33. Antithrombotic Trialists's Collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
34. Kunicki TJ: Influence of platelet collagen receptor polymorphisms in hemostasis and thrombotic disease. Arterioscler Thromb Vasc Biol 2002;22:14-20.
35. Catto AJ: Genetic aspects of the hemostatic system in cerebrovascular disease. Neurology 2001;57(suppl 2):S24-S30.
36. Propping P, Freidl W: Genetic control of adrenergic receptors on human platelets: A twin study. Hum Genet 1983;64:105-109.
37. O'Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, Myers RH, et al: Genetic and environmental contributions to platelet aggregation. The Framingham Heart Study. Circulation 2001;103:3051-3055.
38. Feng DL, Lindpaintner K, Larson MG, Rao VS, O'Donnell CJ, Lipinska I, et al: Increased platelet aggregability associated with platelet GPIIIa polymorphism. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 1999;19:1142-1147.
39. Feng DL, Lindpaintner K, Larson MG, O'Donnell CJ, Lipinska I, Sutherland PA, et al: Platelet glycoprotein IIIa PlA polymorphism, fibrinogen, and platelet aggregability. The Framingham Heart Study. Circulation 2001;104:140-145.
40. Kastrati A, Schömig A, Seyfarth M, Koch W, Elezi S, Böttiger C, et al: PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent replacement. Circulation 1999;99:1005-1010.
41. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AAV, Lie KI, Kastelein JJ: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998;38;86-93.
42. Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E: Antihypertensive pharmacogenetics: Getting the right drug to the right patient. J Hypertens 2001;19:1-11.
43. Niu T, Chen X, Xu X: Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: Therapeutic implications. Drugs 2002;62:977-993.
44. Okamura A, Ohishi M, Rakugi H, Katsuya T, Yanagitani Y, Taniyama Y, et al: Pharmacogenetic analysis of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty. Angiology 1999;50:811-822.
45. Temple S: The development of neural stem cells. Nature 2001;414:112-117.
46. Abe K: Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury. J Cereb Blood Flow Metab 2000;20:1393-1408.
47. Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR, Gebel J, et al: Transplantation of cultured human neuronal cells for patients with stroke. Neurology 2000;55:565-569.
48. Hess DC, Hill WD, Martin-Studdard A, Carrol J, Brailer J, Carothers B: Bone marrow as a source of endothelial cells and NeuN-expressing cells after stroke. Stroke 2002;33:1362-1368.
49. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al: Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001;32:1005-1011.
50. Zhang ZG, Zhang L, Jiang Q, Chopp M: Bone-marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse. Circ Res 2002;90:284-288.
51. Zhao LR, Duan WM, Reyes M, Keene CD, Verfaillie CM, Low WC: Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Exp Neurol 2002;174:11-20.